QUINTA-ANALYTICA have been approved for registration into the Ministère de l’Enseignement Supérieur et de la Recherche (France) Tax Credit system (CIR).

As a European based pharmaceutical company, Quinta are proud to have been granted approval into the French Tax Credit system for at least the next two years, opening the door for our French partners to take advantage of the R&D tax credit benefits offered by the Ministry of Research and Innovation.

The CIR is a public aid which supports the efforts of companies conducting Research and Development (fundamental research, applied research, experimental development) and also Innovation (expenditure for the production of prototypes or installations of new product pilots) via tax credit relief.

If you operate in France and are looking for a EU based partner who can deliver world class service and testing, get in touch to learn more about the tax incentives available to you and how you can offset your investment in research against your corporation tax bill.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.